Top Markets
Coin of the day
Novonesis (Novozymes) B Novonesis (Novozymes) B

Novonesis (Novozymes) B

NSISBC
Rank in Stocks #1197
Established in January 2024 through the amalgamation of Novozymes A/S and Chr.... Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Share Price
$72.44
Last synced: 2026-08-24
Market Cap
$20.13B
Change (1 day)
1.25%
Change (1 year)
17.60%
Country
DK
Trade Novonesis (Novozymes) B (NSISBC)
Revenue for Novonesis (Novozymes) B (NSISBC)
Revenue in Aug 2026 TTM: 0
According to Novonesis (Novozymes) B latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novonesis (Novozymes) B from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$35.45B -
GB
- -
FR
$24.41B -
US
$16.84B -
US
$12.60B -
US